🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

16 recruiting trials

for Recurrent Prostate Adenocarcinoma

Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer NCT05328505NA2 sites📍 London📍 Toronto University Health Network, Toronto · Tests: Image-guided Radiotherapy Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial NCT07466498Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging NCT04423211Phase 3341 sites📍 Anchorage📍 Anchorage📍 Anchorage ECOG-ACRIN Cancer Research Group · Tests: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. NCT06046131NA2 sites📍 Rennes📍 Pointe-à-Pitre Centre Hospitalier Universitaire de la Guadeloupe · Tests: Standard care Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial NCT07650240Phase 21 site📍 Rochester Mayo Clinic · Tests: Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone Jump: MR Simulation For Radiation Therapy Master Protocol NCT04545957NA2 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: MRI Simulator, Radiation Therapy PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE NCT05022914n/a1 site📍 Florence Azienda Ospedaliero-Universitaria Careggi Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy NCT06957691Phase 21 site📍 Boston Shehzad Basaria, M.D. · Tests: fezolinetant - reference formulation, Placebo Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II) NCT07142967NA1 site📍 New York NYU Langone Health · Tests: Stereotactic Body Radiation Therapy (SBRT), Androgen Deprivation Therapy (ADT) Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) NCT06654336Phase 25 sites📍 Hamilton📍 Ottawa📍 Toronto Ontario Clinical Oncology Group (OCOG) · Tests: Recurrence-directed therapy (RDT), ELIGARD 22.5mg An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial NCT06813898EARLY Phase 11 site📍 Chicago Northwestern University · Tests: Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Positron Emission Tomography Flotufolastat F 18 PET in Men With Very Low PSA Recurrence NCT06862856n/a2 sites📍 Boston📍 Boston Massachusetts General Hospital · Tests: Positron Emission Tomography (PET) Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma NCT07150715Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tet… Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring NCT05054296Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Educational Intervention, Exercise Intervention, FitBit, Quality-of-Life Assessment, Questionnaire Administration Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy